SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Norgren M)
 

Search: WFRF:(Norgren M) > (2015-2019) > Design and rational...

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial

Berger, J. S. (author)
Katona, B. G. (author)
Jones, W. S. (author)
show more...
Patel, M. R. (author)
Norgren, L. (author)
Baumgartner, I. (author)
Blomster, Juuso I. (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Mahaffey, K. W. (author)
Held, P. (author)
Millegard, M. (author)
Heizer, G. (author)
Reist, C. (author)
Fowkes, F. G. (author)
Hiatt, W. R. (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2016
2016
English.
In: American Heart Journal. - : Elsevier BV. - 0002-8703. ; 175, s. 86-93
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in peripheral artery disease (PAD) are less compelling. Aspirin has modest evidence supporting a reduction in cardiovascular events in patients with PAD, whereas clopidogrel monotherapy may be more effective in PAD. Ticagrelor, a potent, reversibly binding P2Y(12) receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction. The EUCLID trial is designed to address the need for effective antiplatelet therapy in PAD to decrease the risk of cardiovascular events. Study design EUCLID is a randomized, double-blind, parallel-group, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor compared with clopidogrel for the prevention of major adverse cardiovascular events in subjects with symptomatic PAD. Subjects with established PAD will be randomized in a 1: 1 fashion to ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. The primary end point is a composite of cardiovascular death, myocardial infarction, or ischemic stroke. Other end points address limb events including acute leg ischemia, need for revascularization, disease progression by ankle-brachial index, and quality of life. The primary safety objective is Thrombolysis in Myocardial Infarction-defined major bleeding. Recruitment began in December 2012 and was completed in March 2014; 13,887 patients were randomized. The trial will continue until at least 1,364 adjudicated primary end points occur. Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

ankle-brachial index
acute coronary syndromes
cardiovascular events
heart-association
risk-factors
task-force
aspirin
prevention
prevalence
antagonist
Cardiovascular System & Cardiology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view